Alcohol

# Research Output: Alcohol (Ethanol)

**PSX ID:** PSX-0093  
**Research Date:** 2026-05-07  
**Provenance ID:** fb19813e-f8c7-4269-adbc-f29853ef1f6e

---

## Chemical Identity

**Verified via PubChem CID 702:**

| Property | Value |
|---|---|
| Systematic name | ethanol |
| IUPAC name | ethanol |
| Molecular formula | C₂H₆O |
| Molecular weight | 46.07 g/mol |
| PubChem CID | 702 |
| InChIKey | LFQSCWFLJHTTHZ-UHFFFAOYSA-N |
| SMILES | CCO |
| CAS number | 64-17-5 |

**Notes on seed data:**
- The brief listed SMILES and InChIKey as blank. PubChem confirms InChIKey = LFQSCWFLJHTTHZ-UHFFFAOYSA-N. SMILES = CCO (canonical). These should be populated.
- The brief listed the molecular formula and weight as blank; confirmed C₂H₆O and 46.07 g/mol.
- PubChem CID 702 should be recorded.
- Ethanol is a chiral-free molecule (no stereocenters); no active isomer question applies.

---

## Pharmacology

### Primary Targets and Mechanism

Ethanol acts on multiple molecular targets simultaneously, with no single receptor accounting for all its pharmacological effects. The primary relevant targets are:

**1. GABA-A Receptor (Positive Allosteric Modulation)**

Ethanol is a positive allosteric modulator (PAM) of GABA-A receptors — the principal inhibitory ion channel in the CNS. At intoxicating concentrations (5–50 mM, i.e., BAC ~0.02–0.23%), ethanol potentiates GABA-mediated chloride conductance, producing inhibitory neurotransmission enhancement across the CNS. This mechanism underlies the anxiolytic, sedative, muscle-relaxant, and anticonvulsant properties of acute ethanol exposure (Morris et al. 2025 [Ref 6]; Berro et al. 2019 [Ref 7]).

Subunit selectivity: ethanol has demonstrable effects at α1-, α2-, α3-, and α5-containing GABA-A receptors, with α2/α3-containing receptors implicated in reinforcing and discriminative-stimulus effects in nonhuman primates (Berro et al. 2019 [Ref 7]). α6-containing receptors in the cerebellum may mediate anti-tremor effects at low doses (Huang et al. 2023 [Ref — referenced in search but not separately cited]).

Auxiliary protein Shisa7, associated with GABA-A receptor surface expression, has recently been identified as a key molecular substrate for ethanol's discriminative-stimulus and reinforcing effects; knockdown of Shisa7 attenuates both (Morris et al. 2025 [Ref 6]).

Neurosteroids (e.g., allopregnanolone) are also potent endogenous GABA-A PAMs; ethanol induces neurosteroid synthesis in some brain regions, providing an additional indirect GABAergic mechanism (Finn & Jimenez 2018 [Ref 8]).

No published Ki or EC50 values for ethanol at GABA-A receptors were located; this is consistent with the pharmacological literature noting that ethanol has very low potency and high concentrations required compared to classic benzodiazepines. Cross-tolerance with benzodiazepines, barbiturates, and other GABAergic depressants is well-established (Kumar et al. 2004 [Ref 35]).

**2. NMDA Receptor Antagonism**

In the landmark 1989 Science paper, Lovinger, White & Weight demonstrated that ethanol inhibits NMDA-activated ion current in hippocampal neurons in a concentration-dependent manner over the 5–50 mM range — the same concentrations that produce intoxication in humans. At 50 mM ethanol, NMDA current amplitude was reduced by 61%; kainate and quisqualate currents were reduced by only 18% and 15% respectively. The potency hierarchy for inhibition of NMDA currents across a series of alcohols was linearly correlated with their intoxicating potency (Lovinger et al. 1989 [Ref 12]).

This NMDA antagonism underlies ethanol's impairment of spatial learning, memory consolidation, and higher cognitive functions. NMDA receptor upregulation during chronic alcohol exposure is thought to drive neuronal hyperexcitability during withdrawal (Kang et al. 1998 [Ref — referenced in search]).

Acamprosate (calcium acetylhomotaurinate), a clinically-approved pharmacotherapy for alcohol use disorder, is a weak NMDA antagonist (IC50 ~5.5 mM at hippocampal neurons) that also modulates NMDA subunit expression; its therapeutic mechanism is thought to involve normalization of glutamatergic hyperexcitability during protracted abstinence (Rammes et al. 2001 [Ref 40]).

**3. Dopamine Mesolimbic Reward System**

Ethanol increases dopamine release in the nucleus accumbens (NAc) via disinhibition of ventral tegmental area (VTA) dopamine neurons. The VTA contains both dopamine neurons (positively reinforcing) and GABA inhibitory interneurons; ethanol enhances GABAergic input to VTA GABA neurons through α6-containing nicotinic acetylcholine receptors, ultimately releasing dopamine neurons from tonic inhibition (Wadsworth et al. 2023 [Ref — identified in search]).

VTA dopamine neuron plasticity is critically involved in alcohol reward, seeking, and relapse. GDNF gene therapy targeting VTA in non-human primates ablated alcohol-drinking behavior and corrected hypodopaminergic states (Ford et al. 2023 [Ref — identified in search]).

The incentive-sensitization theory (Robinson & Berridge 2001 [Ref 43]) distinguishes drug "wanting" (incentive salience, mediated by mesolimbic dopamine sensitization) from drug "liking" (pleasure). Chronic alcohol use sensitizes wanting circuits, driving compulsive intake even when hedonic response is reduced.

**4. Adenosine System**

The brief lists "adenosine system" as a pharmacological class. Published data supporting direct adenosine receptor involvement in ethanol's acute psychoactive effects is limited in the sources located. Ethanol inhibits adenosine reuptake, elevating extracellular adenosine levels, which activates A1 receptors and produces sedative/hypnotic effects. This is supported by mechanistic data but direct Ki values from competitive binding assays were not retrieved in this research pass. **FLAG: Adenosine mechanism confirmed as pharmacological class but specific binding affinity data was not located — generation agent should note this as probable but requiring citation.**

**5. Opioid System**

Ethanol stimulates release of endogenous opioid peptides (β-endorphins, enkephalins) which contribute to the pleasurable/euphoric effects of early intoxication. Naltrexone (mu-opioid antagonist) reduces alcohol's rewarding effects and is an FDA-approved AUD treatment, demonstrating the functional importance of this interaction (Ray et al. 2010 [Ref 29]). Nalmefene (mu/delta antagonist, partial kappa agonist) has similar therapeutic efficacy via blocking opioid-mediated reward enhancement (Mann et al. 2016 [Ref 28]).

### Pharmacokinetics

**Absorption:** Ethanol is absorbed primarily from the small intestine (proximal jejunum) and to a lesser extent from the stomach. Absorption rate is highly variable; key factors include fasting vs. fed state (food slows absorption markedly), ethanol concentration (moderate concentrations absorbed faster than very high concentrations which cause pyloric spasm), and co-ingested substances. Absorption is substantially complete within 30–90 minutes under typical conditions (Norberg et al. 2003 [Ref 25]).

**First-pass metabolism:** A portion of ingested ethanol is oxidized during passage through the gastric mucosa and hepatic portal system before reaching systemic circulation ("first-pass effect"). This is more pronounced in men than women, partly due to higher gastric ADH activity in men, contributing to higher blood ethanol concentrations in women at equivalent doses (Norberg et al. 2003 [Ref 25]; Martinez et al. 2010 [Ref 5]).

**Distribution:** Ethanol distributes throughout total body water. Volume of distribution (Vd) = ~0.5–0.7 L/kg in average adults; lower Vd in women and elderly (less total body water as proportion of body mass) explains higher BAC at equivalent mg/kg doses. Ethanol crosses the blood-brain barrier freely; equilibrium between blood and brain occurs rapidly. Ethanol does not bind appreciably to plasma proteins (Norberg et al. 2003 [Ref 25]).

**Metabolism:** ~95–98% of consumed ethanol is metabolized oxidatively, primarily in the liver.

*Pathway 1 — Alcohol dehydrogenase (ADH):* Principal route at moderate BAC. Cytosolic Class I ADH isoenzymes (encoded by ADH1B, ADH1C genes) convert ethanol → acetaldehyde. Km ~0.05–0.1 g/L (very low); enzyme becomes saturated after only a few drinks, producing zero-order (fixed-rate) kinetics at BAC > ~20 mg/100 mL (Cederbaum 2012 [Ref 1]; Jones 2010 [Ref 3]).

*Pathway 2 — CYP2E1 (Microsomal Ethanol Oxidizing System):* Inducible by chronic alcohol; higher Km (~0.5–0.8 g/L), so contributes more at higher BAC and in heavy drinkers. CYP2E1 generates reactive oxygen species (ROS) in addition to acetaldehyde, contributing to oxidative stress and hepatotoxicity (Doody et al. 2017 [Ref 4]; Konishi & Ishii 2007 [Ref 19]).

*Acetaldehyde:* Toxic intermediate; rapidly oxidized to acetate by aldehyde dehydrogenase (ALDH2 in liver mitochondria). Acetaldehyde is classified as IARC Group 1 carcinogen — it forms DNA adducts leading to G→T mutations in single-stranded DNA and is linked to esophageal, oral, head/neck, and other cancers (Vijayraghavan et al. 2022 [Ref 15]; Lachenmeier & Monakhova 2011 [Ref 16]).

**ALDH2 deficiency:** Approximately 540 million East Asians carry the ALDH2*2 allele (dominant negative; inactive enzyme), causing inefficient acetaldehyde clearance after drinking. This manifests as the "Asian flushing response" (facial flushing, tachycardia, nausea) and markedly elevates acetaldehyde exposure per drink, conferring dramatically higher esophageal cancer risk from alcohol consumption (Brooks et al. 2009 [Ref 41]).

*Acetate:* Final product; enters TCA cycle and is oxidized to CO₂ and H₂O in peripheral tissues.

**Elimination kinetics:** At forensically-relevant BAC (>20 mg/100 mL), elimination is approximately zero-order (ADH saturated). Elimination rate:
- Non-fasted moderate drinkers: ~15–20 mg/100 mL/h
- Fasted subjects: ~10–15 mg/100 mL/h
- Heavy drinkers/alcoholics (CYP2E1 induced): ~25–35 mg/100 mL/h
- Range across population: 10–35 mg/100 mL/h (Jones 2010 [Ref 3])

Sex differences: women show higher AUC, higher Cmax, and slightly faster proportional elimination than men, independent of weight-adjusted dose, due to differences in body water fraction and hepatic metabolic capacity (Martinez et al. 2010 [Ref 5]).

Genetic polymorphisms: ADH1B rs1229984 (Arg48His) and ADH1C variants significantly modulate ethanol pharmacokinetics; carriers of certain alleles show decreased metabolic rate (Martinez et al. 2010 [Ref 5]).

**Excretion:** ~2–5% of consumed ethanol is excreted unchanged in breath, urine, and sweat. The breath:blood ratio (~2100:1) is the basis of breathalyzer technology. Renal clearance is minor.

---

## History

### Origins of Fermentation (~7000 BCE onward)

Archaeological evidence from the Jiahu site (Henan Province, China) reveals residues of a fermented beverage containing rice, honey, and fruit dated to ~7000 BCE — among the earliest evidence of intentional alcohol production in human history. Mesopotamian evidence for intentional beer brewing appears c. 3900 BCE (the Sumerian "Hymn to Ninkasi" contains the earliest surviving beer recipe, describing fermentation of barley via bappir bread). Egyptian winemaking is documented from c. 3100 BCE and was integrated into religious and burial practices (Rosso 2012 [Ref 20]; web sources [Ref 47]).

### Distillation History

Early distillation evidence appears on Akkadian cuneiform tablets (~1200 BCE) describing perfumery operations involving primitive still apparatus. More sophisticated alcohol distillation developed during the Islamic Golden Age in the 8th–9th centuries CE (attributed to Jabir ibn Hayyan and al-Kindi), diffused to Europe via Spain and Sicily, and was widely practiced by European alchemists and apothecaries from the 12th century onward. High-proof distilled spirits entered widespread use by the 15th–16th centuries (web source [Ref 47]).

### Medicinal, Religious, and Cultural History

Throughout antiquity, alcoholic beverages were used as antiseptics, anaesthetics, analgesics, and remedies for numerous conditions. Beer and wine held divine status in Mesopotamian and Greek culture (Greek symposia; Dionysian tradition). In Islamic tradition, alcohol was prohibited (haram), laying the cultural foundation for contemporary prohibition policies in Muslim-majority nations (Rosso 2012 [Ref 20]).

### Regulatory and Prohibition History

**United States Prohibition (1920–1933):** The 18th Amendment to the US Constitution, ratified January 16, 1919 (effective January 17, 1920), prohibited manufacture, sale, and transportation of intoxicating liquors. The Volstead Act (1919) defined "intoxicating" as >0.5% ABV. Alcohol consumption dropped ~30%; however, prohibition failed to eliminate alcohol use and generated massive organized crime infrastructure. The 21st Amendment (ratified December 5, 1933) repealed prohibition and returned alcohol regulation to individual states (Wikipedia [Ref 45]).

**Contemporary:** The US minimum drinking age of 21 was established nationwide following the National Minimum Drinking Age Act of 1984 — credited with reducing drink-driving fatalities. Most of the world sets minimum drinking age at 18. Countries with full prohibition include Libya, Somalia, Sudan, and portions of other Muslim-majority nations (Wikipedia [Ref 38]).

---

## Subjective Effects

### BAC-Correlated Dose-Response

Ethanol's subjective and objective effects are closely correlated with blood alcohol concentration (BAC):

| BAC (%) | Effects |
|---|---|
| 0.02–0.05 | Mild relaxation, mood elevation, slight warmth, mild disinhibition, minor impairment of judgment; some find early euphoria |
| 0.05–0.08 | Lowered inhibitions, increased sociability, mild coordination impairment, emotional lability, judgment impairment begins; legal driving limit in most US states is 0.08% |
| 0.08–0.15 | Slurred speech, motor control impairment, reaction time slowing, memory impairment, emotional volatility, nausea possible |
| 0.15–0.25 | Pronounced sedation, ataxia, confusion, severe memory impairment, possible blackout (anterograde amnesia) |
| 0.25–0.30 | Stupor, reduced responsiveness, severe motor impairment, risk of unconsciousness |
| 0.30–0.40 | Possible coma, irregular breathing, significant mortality risk |
| ≥0.40 | Lethal threshold — risk of cardiorespiratory arrest; death common (web source [Ref 37]) |

The seed data notes "Death from ethanol consumption is possible when blood alcohol levels reach 0.4%" — this is **confirmed** by multiple clinical references as an approximate lethal threshold; the exact lethal concentration varies with individual tolerance, body weight, rate of consumption, and concurrent substances [Ref 37].

### Published Subjective Effect Descriptions

From controlled studies: acute low-to-moderate doses produce anxiety suppression, disinhibition, sociability enhancement, warmth, and mild euphoria. Higher doses produce sedation, cognitive impairment, amnesia, and emotional lability. The "biphasic" alcohol response theory posits that ascending BAC (during absorption) is associated with more stimulant/euphoric effects while descending BAC is associated with more sedative/dysphoric effects — this subjective asymmetry shapes patterns of use.

**Sleep effects:** Alcohol reduces sleep onset latency at all doses; consolidates and increases slow-wave sleep (SWS/delta) in the first half of the night across dose and gender. Total night REM sleep is decreased at moderate and high doses; REM sleep onset is significantly delayed at all doses. Second-half sleep is disrupted regardless of dose — leading to characteristic early morning waking. This biphasic sleep pattern can drive self-medication cycles: insomnia self-treated with alcohol, producing brief initial benefit followed by worsening underlying sleep architecture (Ebrahim et al. 2013 [Ref 44]).

### Effect Profile Analysis (Seed Data — 49 slugs, all null values)

All 49 effects in the seed profile lack intensity/frequency values (all community_consensus_large/medium provenance). The following assessments are based on published pharmacological and clinical data and should guide editorial assignment:

**Perception effects (confirmed in literature):**
- visual-acuity-suppression: well-documented at intoxicating doses
- double-vision: documented at higher BAC (nystagmus, oculomotor impairment)
- after-images, sleep-transition-hallucinations: documented at higher doses in sleep transitions; less well-studied
- touch-suppression: pain-suppression documented; tactile sensitivity reduction well-known
- music-enhancement, olfactory-hallucination: less well-characterized; olfactory-hallucination primarily at very high doses or during withdrawal

**Body effects (confirmed):**
- sedation: STRONG, UNIVERSAL — primary effect
- motor-control-impairment: STRONG, UNIVERSAL
- muscle-relaxation: well-documented via GABA-A mechanism
- nausea, vomiting: well-documented, particularly at higher doses
- dizziness: well-documented
- headache: classically associated with hangover
- dehydration-sensation: classic hangover feature; ethanol inhibits ADH (antidiuretic hormone), causing increased urination and dehydration
- increased-urination: well-documented
- respiratory-depression: at higher doses; critical safety concern
- temperature-dysregulation: ethanol causes peripheral vasodilation and heat loss despite initial warmth sensation
- sexual-arousal-enhancement at low doses / sexual-arousal-suppression at higher doses: classic dose-dependent biphasic effect
- abnormal-heartbeat: documented; alcohol is the most common cause of "holiday heart syndrome" (paroxysmal atrial fibrillation after binge)
- excessive-sweating: documented, especially during hangover
- appetite-enhancement and appetite-suppression: complex; low-moderate doses often increase appetite; heavy intoxication suppresses

**Thinking effects (confirmed):**
- cognitive-impairment, focus-suppression, analysis-suppression, memory-suppression: strongly confirmed
- delusions-of-sobriety: classically documented — intoxicated individuals typically underestimate their degree of impairment
- delirium: at very high BAC or during withdrawal
- thought-deceleration, information-processing-suppression: well-documented
- language-suppression: slurred speech, word-finding difficulty at moderate-high BAC
- pattern-recognition-suppression: documented
- creativity-suppression: at moderate-high doses (though commonly perceived as enhanced at low doses — this is largely a disinhibition effect)
- compulsive-redosing-urge: well-documented in AUD context
- cognitive-fatigue: documented

**Feeling effects (confirmed):**
- anxiety-suppression: primary effect at low doses; one major driver of use
- depression: long-term effect and following binge (next-day dysphoria)
- emotional-enhancement, emotional-lability: documented
- empathy-enhancement: reported at low doses
- irritability: particularly during hangover/withdrawal

**Self effects (confirmed):**
- disinhibition: core pharmacological effect, strongly confirmed
- sociability-enhancement: at low-moderate doses
- ego-inflation: documented at low doses
- self-control-suppression: strongly confirmed

**Time effects:**
- temporal-disorientation: at moderate-high doses

**FLAG for generation agent:** All 49 effect slugs require intensity and frequency values. Based on pharmacological evidence, highest-intensity effects should include: sedation, cognitive-impairment, motor-control-impairment, disinhibition, anxiety-suppression, memory-suppression. Universal/common effects include: muscle-relaxation, nausea, dizziness, dehydration-sensation, increased-urination. Less universal/dose-dependent: respiratory-depression (higher doses), delirium (very high or withdrawal), hallucinations.

---

## Safety & Toxicity

### Lethal Dose

**In humans:** BAC ≥0.40% (400 mg/100 mL) is associated with risk of death from cardiorespiratory arrest. Exact lethal BAC varies substantially with individual tolerance, rate of consumption, and polydrug use. In habitual heavy drinkers, tolerance shifts the lethal threshold higher; in naive users, lower BAC may be fatal. No precise human LD50 exists in the literature; animal LD50 data are not directly applicable to humans at physiologically relevant concentrations [web source Ref 37].

### Hepatotoxicity

Chronic ethanol use causes a spectrum of alcohol-associated liver disease (ALD):
1. **Hepatic steatosis (fatty liver):** Reversible; occurs in ~90% of heavy drinkers. Driven by NADH excess from ADH-mediated ethanol oxidation, stimulating fatty acid synthesis and inhibiting oxidation.
2. **Alcoholic steatohepatitis (ASH):** Inflammatory progression; requires continued heavy use plus other risk factors.
3. **Alcoholic hepatitis (AH):** Acute inflammatory syndrome with jaundice, coagulopathy, and risk of acute-on-chronic liver failure. 28-day mortality can reach 30–50% in severe cases.
4. **Cirrhosis:** Irreversible fibrosis; develops in 10–20% of heavy drinkers.

Mechanisms: acetaldehyde-induced cytotoxicity, CYP2E1-generated ROS and oxidative stress, lipid peroxidation products (4-HNE) stimulating collagen synthesis, TNF-α activation of Kupffer cells, mitochondrial damage (Lieber 2004 [Ref 17]; Crabb et al. 2019 [Ref 10]).

**Hepatocellular carcinoma (HCC):** Alcohol is a major cause of cirrhosis-mediated HCC. Risk factors: amount consumed, female sex, genetic polymorphisms, smoking, obesity, viral hepatitis co-infection (Jacob et al. 2023 [Ref 18]).

### Carcinogenicity

Acetaldehyde (the primary metabolite of ethanol) is classified as an **IARC Group 1 carcinogen**. Alcohol-associated cancers include: esophageal (squamous cell), oral, oropharyngeal, laryngeal, liver, colorectal, and female breast cancer. The cancer risk per drink is substantially elevated in individuals with ALDH2 deficiency (Asian flushing response carriers) due to higher acetaldehyde exposure (Vijayraghavan et al. 2022 [Ref 15]; Brooks et al. 2009 [Ref 41]).

WHO 2016 data: alcohol-attributable cancer deaths contributed 12.6% of all alcohol-attributable deaths globally (WHO 2018 [Ref 36]).

### Neurological Toxicity

**Wernicke-Korsakoff Syndrome:** Thiamine (vitamin B1) deficiency secondary to chronic alcohol use causes Wernicke encephalopathy (acute: ophthalmoplegia, ataxia, confusion triad; often incomplete presentation) which, if untreated, progresses to Korsakoff syndrome (permanent amnestic disorder). High-dose intravenous thiamine is the emergency treatment; early administration can prevent progression. Radiological improvement on MRI does not reliably predict cognitive recovery (case report literature [Refs found in search]).

**Peripheral neuropathy:** Distal symmetric sensorimotor polyneuropathy; mechanism involves acetaldehyde toxicity and thiamine deficiency.

**Alcoholic cardiomyopathy:** Dilated cardiomyopathy with congestive heart failure. Attributable to direct ethanol and acetaldehyde toxicity to cardiac myocytes.

**Holiday Heart Syndrome:** Paroxysmal atrial fibrillation and other arrhythmias following binge drinking in otherwise healthy individuals.

### Fetal Alcohol Spectrum Disorder (FASD)

Prenatal ethanol exposure causes fetal alcohol spectrum disorders — a continuum of permanent neurodevelopmental and structural defects, including fetal alcohol syndrome (FAS). Ethanol and acetaldehyde cross the placenta freely; fetal enzymes have very low alcohol-metabolizing capacity. Affects an estimated 1 in 20 school-age children in the US. No safe amount of alcohol during pregnancy is established. FASD involves cortical malformation, hippocampal damage, prefrontal circuit dysfunction, and persistent cognitive/behavioral impairment. Redox dysregulation and NMDA receptor disruption are key teratogenic mechanisms (Leroy et al. 2026 [PMID 41839574 — found in search]).

### Global Mortality Burden

WHO 2018 report: >3 million deaths in 2016 attributable to harmful alcohol use, representing 1 in 20 global deaths; >75% among men. More than 5% of global disease burden. By cause: injuries 28.7%, digestive diseases (primarily cirrhosis/pancreatitis) 21.3%, cardiovascular disease 19.0%, infections 12.9%, cancers 12.6% (WHO 2018 [Ref 36]).

Sohi et al. 2021 (Rehm group): In under-69 population in 2016, 2.0 million premature deaths and 117.2 million DALYs attributable to alcohol. Leading causes: cirrhosis 457,000 deaths, road injuries 338,000, tuberculosis 190,000. Highest per-capita burden in Eastern Europe (Sohi et al. 2021 [Ref 33]).

---

## Harm Reduction

### Key Risk Factors
1. **Dose:** Risk of acute toxicity, aspiration, and blackout increases substantially above ~0.15% BAC. Dose titration and tracking standard drinks (1 US standard drink = 14 g pure ethanol) are primary harm reduction strategies.
2. **Rate of consumption:** Rapid consumption overwhelms ADH, producing faster BAC rise. Pacing intake reduces peak BAC.
3. **Fasted state:** Consuming alcohol without food dramatically accelerates absorption and elevates peak BAC.
4. **Body weight and sex:** Women achieve higher BAC per gram of alcohol due to lower Vd and gastric first-pass; women also develop ALD faster and at lower doses than men (Devaud et al. 1998 [Ref 23]).
5. **Polydrug combinations:** See Interactions section. Simultaneous CNS depressants (opioids, benzodiazepines, GHB, ketamine) carry lethal risk.
6. **Driving:** BAC ≥0.08% (US legal limit) is associated with significantly elevated crash risk; impairment begins at lower BAC (Eichelberger 2026 [Ref found in search]).

### Harm Reduction Strategies (Evidence-based)
- Eating before/during drinking to slow absorption
- Alternating with water to reduce total consumption and mitigate dehydration
- Avoiding mixing with other CNS depressants
- Using breathalyzers or drink-tracking apps before driving decisions
- Thiamine supplementation for heavy/chronic users to prevent Wernicke encephalopathy
- Naloxone awareness for social settings where opioid co-use may occur

### Contraindications (Absolute)
- Pregnancy (any amount poses FASD risk)
- Concurrent opioid analgesic use without medical supervision
- Concurrent benzodiazepine use without medical supervision
- Concurrent GHB/GBL use (synergistically lethal CNS depression)
- Disulfiram therapy (causes severe acetaldehyde accumulation reaction)
- Hepatic cirrhosis/severe liver disease
- Operating motor vehicles or heavy machinery

### Emergency Response
**Alcohol poisoning:** Signs — unconsciousness, irregular/slow breathing (<8 breaths/min), cold/clammy skin, pallor, seizures. Response: recovery position (to prevent aspiration); call emergency services immediately; do NOT leave alone; do NOT give coffee; do NOT induce vomiting if unconscious. BAC ≥0.40% is life-threatening [Ref 37].

---

## Tolerance & Dependence

### Tolerance

**Acute (metabolic) tolerance:** Behavioral tolerance develops within a single drinking session on the descending limb of the BAC curve (the Mellanby effect). At the same BAC, impairment is greater on the ascending than descending limb.

**Chronic metabolic tolerance:** CYP2E1 induction by repeated ethanol exposure increases hepatic metabolism rate by up to 2–3× in heavy drinkers (elimination rate up to 35 mg/100 mL/h vs 15 mg/100 mL/h in non-drinkers) (Jones 2010 [Ref 3]).

**Neuroadaptive (functional) tolerance:** The most clinically significant form. Chronic ethanol exposure drives GABA-A receptor downregulation and subunit composition changes (decreased α1, changes in α4/δ expression), reducing the receptor's sensitivity to both ethanol and benzodiazepines. Simultaneously, NMDA receptor upregulation occurs, shifting the excitatory/inhibitory balance in the direction of hyperexcitability. This neuroadaptation underlies both tolerance and withdrawal risk (Kumar et al. 2004 [Ref 35]; Devaud et al. 1998 [Ref 23]).

**Seed data states:**
- Buildup: "develops with prolonged and repeated use" — **confirmed** by published literature
- Half-life: 5 days — **FLAG: The tolerance half-life of 5 days requires editorial review. The PK half-life of ethanol itself is not 5 days (elimination is typically complete in hours). This value likely refers to tolerance decay half-life, but no primary source was located to verify this specific number. Recommend flagging for editorial review.**
- Full reset: 1.5 weeks — **FLAG: Similar concern; no primary source was located to verify this tolerance reset period specifically.**
- Cross-tolerances: GABA, depressants — **confirmed** by published literature (Kumar et al. 2004 [Ref 35])

### Dependence

**Formation:** Ethanol has extremely high physical and psychological dependence liability. DSM-5 AUD criteria: 2+ of 11 criteria in 12 months, ranging from loss of control, craving, withdrawal, tolerance, to continued use despite harm (Grant et al. 2015 [Ref 32]).

**Epidemiology:** NESARC-III (2012–2013, n=36,309): 12-month prevalence of DSM-5 AUD was 13.9%; lifetime prevalence was 29.1% — making AUD one of the most common psychiatric disorders in the US (Grant et al. 2015 [Ref 32]).

### Withdrawal Syndrome

Alcohol withdrawal syndrome (AWS) is a potentially life-threatening syndrome arising from abrupt cessation or marked reduction in heavy chronic alcohol use. The neurobiological basis is rebound CNS hyperexcitability driven by NMDA upregulation and GABA-A downregulation from chronic alcohol-induced neuroadaptation.

**Clinical timeline:**
- 6–24 hours: tremor, anxiety, insomnia, tachycardia, hypertension, diaphoresis, nausea; minor withdrawal
- 12–48 hours: risk of generalized tonic-clonic seizures (often single, brief)
- 48–72 hours: risk of delirium tremens (DTs) — the most severe form: agitation, fever, confusion, hallucinations (visual, tactile, auditory), autonomic instability; untreated mortality 5–15%; treated mortality ~1–2%

Assessment: Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is the standard instrument for AWS severity quantification (Desai et al. 2024 [Ref 22]).

**Treatment:** Benzodiazepines (diazepam, chlordiazepoxide, lorazepam) are first-line due to cross-tolerance at GABA-A receptors (Desai et al. 2024 [Ref 22]). Phenobarbital is increasingly used in severe AWS. Adjunct: thiamine supplementation mandatory; antipsychotics for hallucinations; beta-blockers for autonomic symptoms. Symptom-triggered therapy (guided by CIWA-Ar) reduces total benzodiazepine dose and treatment duration vs. fixed-dose regimens (various clinical studies in search).

**Seed data:** Dependence formation: "extremely addictive with a high potential for abuse" — **confirmed**.

---

## Interactions

### Lethal Combinations (seed data confirmed/clarified)

**GHB and GBL — LETHAL:** Both ethanol and GHB/GBL are CNS depressants acting partly via GABA-B receptors and other mechanisms. Combination produces synergistic CNS and respiratory depression. GHB's steep dose-response curve makes polydrug combination particularly dangerous; even minor additional CNS depression can shift from conscious sedation to coma. European poison center data confirm worsened clinical outcomes when GHB/GBL is combined with ethanol (Miro et al. 2017 [Ref 26]).

**Opioids (heroin, morphine, oxycodone, codeine, fentanyl, hydromorphone, methadone, etc.) — LETHAL:** Synergistic respiratory depression via parallel CNS pathways. Both opioids (mu-receptor-mediated) and ethanol (GABAergic/NMDA) depress respiratory drive; combination substantially lowers the lethal threshold for each. Forensic toxicology consistently identifies ethanol as the most common co-substance in opioid overdose fatalities (Nielsen et al. 2015 [Ref found in search]).

**Benzodiazepines (alprazolam and others) — DANGEROUS to LETHAL:** Cross-tolerant at GABA-A receptors; high-dose combination produces respiratory depression. Polydrug fatalities involving benzodiazepines + ethanol are common.

**Tramadol — LETHAL (seed data):** Tramadol has both opioid (mu) and serotonergic/noradrenergic mechanisms; combination with alcohol potentiates both respiratory depression and CNS depression.

**Ketamine — LETHAL (seed data):** Both are CNS depressants; combination produces synergistic sedation and respiratory depression risk.

**Methoxetamine — LETHAL (seed data):** Dissociative + CNS depressant combination, risk of respiratory compromise and aspiration.

**Baclofen — LETHAL (seed data):** GABA-B agonist; synergistic CNS/respiratory depression with ethanol. Baclofen paradoxically is also used as an off-label AUD treatment; the therapeutic window is narrow and combination with active heavy drinking is dangerous.

**Acetylfentanyl, sufentanil, buprenorphine, other opioids — LETHAL:** Same mechanism as above; acetylfentanyl and sufentanil are extremely potent opioids where small amounts combined with ethanol can be rapidly fatal.

**Dextromethorphan (DXM) — LETHAL (seed data):** High-dose DXM is a dissociative; combination with ethanol produces additive CNS depression.

**Kratom — LETHAL (seed data):** Contains mitragynine (partial mu-opioid agonist); synergistic respiratory depression with ethanol. Case reports of fatalities document this combination.

**Cocaine — DANGEROUS:** Cocaine + ethanol → cocaethylene formation in the liver (via ethanol-facilitated transesterification). Cocaethylene is pharmacologically active (equipotent to cocaine at DAT), has longer half-life (~2h vs ~1h for cocaine), greater cardiotoxicity, higher dopaminergic effects, and lower LD50 in some animal models than cocaine alone. The combination produces enhanced euphoria and increased cardiovascular toxicity (heart rate, myocardial oxygen demand). Human controlled study confirmed enhanced subjective euphoria, elevated HR, elevated cortisol vs cocaine alone (Farre et al. 1997 [Ref 27]; Jones 2019 [Ref 31]).

**PCP — DANGEROUS (seed data):** PCP is a dissociative with CNS depressant properties at high doses; combination amplifies disorientation and respiratory risk.

**Myristicin — DANGEROUS (seed data):** Myristicin (component of nutmeg) has CNS effects; the dangerous interaction likely reflects combined anticholinergic/hallucinogenic and CNS depressant activity.

**Rolicyclidine — DANGEROUS (seed data):** Arylcyclohexylamine dissociative; combination risks similar to PCP.

**LSD — CAUTION (seed data):** No established pharmacokinetic interaction; the caution classification likely reflects unpredictable subjective effects and impaired judgment/decision-making when combining stimulating psychedelic effects with GABAergic sedation. Anecdotally reported to worsen LSD experience.

**Alprazolam — DANGEROUS (seed data):** Benzodiazepine + alcohol GABAergic synergism; respiratory depression and sedation. **FLAG: Seed data inconsistency — alprazolam is listed as "dangerous" but other benzodiazepines are not individually listed; the overall benzodiazepine class should be designated "dangerous" to "lethal" depending on dose.**

### Pharmacokinetic Interaction Mechanism (Ethanol + Other Drugs)

Ethanol acutely inhibits hepatic CYP enzymes (especially CYP3A4, CYP2E1), slowing metabolism of many co-administered drugs and elevating their plasma concentrations. Chronic heavy alcohol use induces CYP2E1, increasing metabolism of acetaminophen to its hepatotoxic metabolite NAPQI and lowering analgesic efficacy of some drugs while increasing their hepatotoxicity. This explains the heightened risk of acetaminophen hepatotoxicity in heavy drinkers even at therapeutic acetaminophen doses (Chan & Anderson 2014 [Ref 2]).

---

## Tolerance & Dependence (Treatment)

### Approved Pharmacotherapies

1. **Naltrexone (oral/injectable):** Mu-opioid receptor antagonist; reduces craving and heavy drinking days. OPRM1 A118G (Asn40Asp) variant predicts stronger naltrexone response. Efficacy: moderate; number needed to treat ~8–12 (Ray et al. 2010 [Ref 29]).

2. **Acamprosate (calcium acetylhomotaurinate):** NMDA/GABA modulator; reduces protracted abstinence symptoms and craving during early recovery. Particularly effective for maintaining abstinence in alcohol-dependent patients who have already detoxified. Mechanism: normalizes glutamatergic hyperexcitability during protracted abstinence (Rammes et al. 2001 [Ref 40]; Heilig & Egli 2006 [Ref 48]).

3. **Disulfiram:** Irreversible ALDH inhibitor. Causes severe aversive reaction (flushing, tachycardia, vomiting, headache, hypotension — the "disulfiram-ethanol reaction") if alcohol consumed. Effectiveness depends on medication adherence/supervision; used primarily as aversion/deterrent therapy (Heilig & Egli 2006 [Ref 48]).

4. **Nalmefene (EU, not FDA-approved):** Mu/delta antagonist, partial kappa agonist; reduces heavy drinking days. Meta-analysis: Hedges g = −0.20 ITT, −0.33 in target population (Mann et al. 2016 [Ref 28]).

### Off-label Pharmacotherapies

- **Baclofen (GABA-B agonist):** Approved for AUD in France and Italy; evidence mixed internationally; narrow therapeutic window when combined with active drinking.
- **Topiramate (AMPA/kainate antagonist, GABA-A PAM):** Significant evidence base; reduces heavy drinking days.
- **Gabapentin:** VGCC modulator; evidence for reducing withdrawal symptoms and alcohol use.
- **GLP-1 receptor agonists:** Emerging real-world data suggesting reduced alcohol consumption as secondary effect (Gougol et al. 2026 [Ref found in search]).

---

## Legal Status

Ethanol in beverage form is a **legal, regulated substance** in the vast majority of the world's jurisdictions, making it uniquely unrestricted among psychoactive compounds.

| Jurisdiction | Status |
|---|---|
| United States | Legal; minimum drinking age 21 (National Minimum Drinking Age Act, 1984); state-level production/distribution regulation |
| United Kingdom | Legal; minimum drinking age 18 |
| European Union | Legal; minimum drinking age 18 (most member states; Germany/Austria allow beer/wine at 16) |
| Canada | Legal; minimum drinking age 18 (AB, MB, QC) or 19 (other provinces/territories) |
| Australia | Legal; minimum drinking age 18 |
| Saudi Arabia, Iran, Pakistan | Prohibited (Islamic law/national law) |
| Libya, Somalia, Sudan | Complete prohibition |
| India | State-level regulation; some states prohibit; drinking age 18–25 depending on state |

There is no scheduling equivalent for ethanol under the US Controlled Substances Act; it is regulated under the Alcohol and Tobacco Tax and Trade Bureau (TTB). Industrial/non-beverage ethanol is regulated separately.

**Analog Act applicability:** Not applicable — ethanol is not controlled.

---

## Clinical Trials

Selected relevant active/completed trials:

| NCT ID | Title | Status | Phase | Condition | Sponsor |
|---|---|---|---|---|---|
| NCT00656630 | Acamprosate vs. Naltrexone (COMBINE genetics) | Completed | Phase 2 | Alcoholism | Scripps Research Institute |
| NCT05492942 | Records for Alcohol Care Enhancement (RACE) | Completed | N/A | Alcohol Use Disorder | Boston Medical Center |
| NCT06303778 | Smartphone App + Medications for Heavy Drinking | Recruiting | N/A | Alcohol Use Disorder | VA Research |
| NCT04287790 | Promoting Medications for AUD on Medicine Service | Terminated | N/A | Alcohol Use Disorder | Yale University |

Note: Active research areas include GLP-1 receptor agonists for AUD reduction (off-label observation), GDNF gene therapy for relapse prevention (nonhuman primate studies), and cannabidiol/psilocybin as adjunct therapies (early-stage human trials referenced in search).

---

## Community Feedback Analysis

No community feedback was submitted for this substance (Part A2 of the brief is empty).

---

## Gaps & Flags

### Safety-Critical Values Requiring Review

1. **FLAG — Tolerance half-life (5 days) and full reset (1.5 weeks):** Seed data values could not be confirmed against published primary sources. The PK half-life of ethanol itself is hours, not days. The 5-day / 1.5-week values may refer to functional tolerance decay (neuroadaptive tolerance normalization), but no primary pharmacology source was located to verify these specific numbers. **Editorial review required before publication.**

2. **FLAG — Lethal BAC threshold (seed data 0.4%):** The seed data states "Death from ethanol consumption is possible when blood alcohol levels reach 0.4%." This is **approximately confirmed** by clinical references as the threshold above which mortality risk is substantial. However, this should be presented as an approximate threshold, not a precise lethal limit — individual variation is large.

3. **FLAG — Baclofen interaction (LETHAL in seed):** Baclofen is simultaneously classified as a potentially lethal interaction in the interaction list AND is used as an AUD treatment. This apparent contradiction should be addressed: therapeutic baclofen doses combined with active heavy drinking can be dangerous/lethal, but medically supervised baclofen therapy is a recognized treatment approach. The generation agent should clarify dose context.

4. **FLAG — Alprazolam (DANGEROUS) vs. other benzodiazepines:** Alprazolam is listed as "dangerous" but no other benzodiazepines appear individually in the interaction list. The overall benzodiazepine class should be covered; alprazolam is not uniquely more dangerous than other benzodiazepines combined with alcohol.

5. **FLAG — Adenosine system mechanism:** Listed as primary pharmacological class but no primary binding affinity data (Ki/EC50) was located. The mechanism (ethanol inhibiting adenosine reuptake → elevated extracellular adenosine → A1 activation) is pharmacologically plausible and referenced in review literature, but was not confirmed by primary experimental data in this research pass. Suggest noting as mechanistic inference if no specific citation available.

6. **FLAG — SMILES, InChIKey, molecular formula/weight all blank in seed data:** All confirmed via PubChem; these should be populated (CCO / LFQSCWFLJHTTHZ-UHFFFAOYSA-N / C₂H₆O / 46.07 g/mol).

### Dose/Duration Data Notes

**Dose (seed):** Doses expressed in grams. A single US standard drink contains 14 g ethanol; one UK unit = 8 g ethanol. The dose ranges (Threshold 10g, Light 10–20g, Common 20–30g, Strong 30–40g, Heavy 40+g) appear broadly consistent with published pharmacokinetic data for observable intoxication effects, though these represent ethanol mass consumed rather than achieved BAC (which is the primary determinant of pharmacological effect). No primary literature verification of these exact numbers was located; however, they are consistent with standard drink guidelines. **Recommend generation agent verify against NIAAA or equivalent published dosing frameworks.**

**Duration (seed):** Onset 2–5 min, come-up 15–45 min, peak 30–90 min, total 1.5–5 hours — broadly consistent with published pharmacokinetic data. **Confirmed approximately.**

### Data Absent or Sparse

- No specific Ki/EC50 data for ethanol at GABA-A receptors were located (ethanol is an atypical receptor modulator with concentrations in the mM range, unlike typical drugs with nM/µM affinities)
- Stereochemistry: ethanol has no chiral centers; not applicable
- No published studies were located on ethanol testing/identification recommendations specific to harm reduction (standard drink counting and breathalyzers are the practical tools)
- Detailed psychedelic-type or transpersonal effects: not applicable to ethanol under normal dosing conditions